Profile
ACHL VRTX REGN ALNY SGEN ARGX
Company Name Achilles Therapeutics plc Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Seagen Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $60.83M $100.71B $61.41B $58.84B $43.15B $40.18B
Employees 0.20K 6.10K 15.16K 2.23K 3.26K 1.60K
CEO Iraj Ali Reshma Kewalramani FASN, Leonard S. Schleifer Yvonne L. Greenstreet David R. Epstein Timothy Van Hauwermeiren EMBA,
Ratings
ACHL VRTX REGN ALNY SGEN ARGX
Quant Rating Score 3 3 4 1 3 4
Quant Rating Neutral Neutral Buy Strong Sell Neutral Buy
Trading
ACHL VRTX REGN ALNY SGEN ARGX
Last Close $1.48 $387.18 $587.65 $451.2 $228.74 $708.09
High 52 $1.49 $516.74 $1201.76 $467.71 $228.74 $708.09
Low 52 $0.7 $366.54 $482.92 $224.58 $228.74 $514.23
Price vs. 52 Week High -0.67 % -25.07 % -51.1 % -3.53 % 0 % 0 %
Price vs. 52 Week Low 111.43 % 5.63 % 21.69 % 100.91 % 0 % 37.7 %
Total Return
ACHL VRTX REGN ALNY SGEN ARGX
1 Month Return 0 % -17.56 % 4.36 % 37.22 % 0 % 19.61 %
3 Month Return 0 % -13.21 % -2.56 % 55.44 % 0 % 22.2 %
6 Month Return 6.86 % -18.4 % -16.41 % 90.29 % 0 % 13.38 %
9 Month Return 38.32 % -16.66 % -22.15 % 77.82 % 0 % 15.21 %
YTD Return 29.82 % -3.85 % -17.5 % 91.75 % 0 % 15.14 %
1 Year Return 96.7 % -19.39 % -51.1 % 60.99 % 0 % 37.06 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACHL VRTX REGN ALNY SGEN ARGX
Dividend Yield Percentage (TTM) - - 0.45 % - - -
Dividend Paid and Capex Coverage Ration (TTM) -25.21 % 11.09 % 4.37 % -0.43 % -5.87 % -44.32 %
Dividend Per Share (TTM) - - 2.64 % - - -
Payout Ratio (TTM) - - 4.18 % - - -
Growth
ACHL VRTX REGN ALNY SGEN ARGX
Asset Growth -26.73 % -0.87 % 14.15 % 10.71 % -1.21 % 36.55 %
Gross Profit Growth -28.3 % 10.25 % 8.23 % 26.81 % 22.93 % 77.08 %
Revenue Growth - 11.66 % 8.27 % 22.97 % 24.65 % 78.6 %
Revenue 3 Year - 45.6 % -13.44 % 147.1 % 91.56 % 275.84 %
Revenue 5 Year - 163.93 % 82.78 % 775.72 % 215.48 % 1701.04 %
Revenue 10 Year - 1632.15 % 429.43 % 2487.4 % 494.04 % 5950.81 %
EBIT Growth -5.82 % -93.69 % 13.17 % 24.59 % - 128.87 %
Net Income Growth 2.12 % -114.8 % 11.61 % 36.82 % 9.51 % 382.34 %
Net Income 3 Yeari Growth Per Share -113.25 % -122.89 % -46.47 % 69.73 % -763.59 % 274.39 %
Net Income 5 Yeari Growth Per Share 86.28 % -145.38 % 111.07 % 73.13 % -276.93 % 396.61 %
Net Income 10 Yeari Growth Per Share 86.28 % 33.84 % 1232.49 % 55.09 % -624.16 % 938.02 %
Operating Income Growth 3.99 % -106.08 % -1.39 % 37.31 % 10.13 % 94.91 %
Operating Cash Flow Growth (CFG) 18.62 % -113.93 % -3.78 % -107.98 % 9.07 % 80.31 %
Operating 3 Year CFG -94.98 % -118.65 % -38.85 % 98.8 % -147.99 % 88.36 %
Operating 5 Year CFG -8546.04 % -131.3 % 84.11 % 97.44 % -195.86 % -135.21 %
Operating 10 Year CFG -8546.04 % 12.43 % 517.51 % 97.08 % -2622.09 % -64 %
EPS Growth 4.4 % -114.8 % 10.39 % 38.64 % 10.81 % 369.77 %
EPS Diluted Growth 4.4 % -114.97 % 10.27 % 38.64 % 10.81 % 347.67 %
Book Value Per Share -29.25 % -6.59 % 11.76 % 129.75 % -9.83 % 28.16 %
Share Holder 3 Year Equity Growth Per Share -23.6 % 62.6 % 53.21 % -89.42 % 33.72 % 85.14 %
Share Holder 5 Year Equity Growth Per Share -84.77 % 168.85 % 167.88 % -96.01 % 220.81 % 200.53 %
Share Holder 10 Year Equity Growth Per Share -84.77 % 1265.7 % 1113.59 % -95.83 % 691.19 % 1039.11 %
Dividend Per Share Growth - - - - - -
Dividend 3 Year Growth Per Share - - - - - -
Dividend 5 Year Growth Per Share - - - - - -
Dividend 10 Year Growth Per Share - - - - - -
Debt Growth -46.19 % 116.42 % 0.06 % 2.27 % -23.28 % 95.27 %
Free Cash Flow Growth 26.1 % -124.1 % -0.08 % -201.54 % 3.67 % 67.46 %
Updated On 31 Dec 2023 31 Dec 2024 31 Dec 2024 31 Dec 2024 31 Dec 2022 31 Dec 2024
Profitability
ACHL VRTX REGN ALNY SGEN ARGX
Gross Profit Margin TTM - 86.11 % 81.98 % 83.64 % 79.1 % 65.32 %
Return on Assets TTM -39.32 % 15.13 % 11.67 % -6.99 % -16.61 % 15.06 %
Return on Equity TTM -41.47 % 22.14 % 15.11 % -274.21 % -20.8 % 18.96 %
Return on Capital Employed TTM -50.39 % 19.72 % 11.45 % -5.52 % -21.46 % 5.04 %
Net Income Per EBT TTM 99.96 % 83.16 % 91.46 % 84.06 % 101.33 % 237.3 %
EBT Per Ebit TTM 91.92 % 111.48 % 123.23 % 210.66 % 98.26 % 147.38 %
EBIT Per Revenue TTM - 34.36 % 27.83 % -7.32 % -31.24 % 13.47 %
Cash Flow To Debt Ratio TTM -483.77 % 251.83 % 175.35 % -1.2 % -1043.73 % -175.92 %
Receivables Turnover TTM - 6.03 2.53 4.34 3.91 1.91
Payables Turnover TTM 0.56 0.43 3.54 3.93 1.97 0.88
Inventory Turnover TTM - 1.06 0.8 5.62 0.96 2.21
Fixed Asset Turnover TTM - 431.08 % 293.64 % 355.68 % 665.41 % 5009.77 %
Asset Turnover TTM - 47.51 % 37.19 % 53.92 % 53.41 % 31.97 %
Operating Cash Flow Per Share TTM -0.43 14.98 45.13 -0.12 -2.46 -1.07
Free Cash Flow Per Share TTM -0.45 13.63 36.58 -0.4 -2.88 -1.09
Cash Per Share TTM 212.86 % 3036 % 7107.14 % 2203.63 % 939.52 % 5536.58 %
Operating Cash Flow Sales Ratio TTM - 33.68 % 33.37 % -0.63 % -23.12 % -3.31 %
Free Cash Flow Operating Cash Flow Ratio TTM 103.97 % 90.99 % 81.05 % 335.21 % 117.04 % 102.26 %
Cash Flow Coverage Ratios TTM -483.77 % 251.83 % 175.35 % -1.2 % -1043.73 % -175.92 %
Price To Free Cash Flows Ratio TTM -3.34 28.78 15.97 -1129.68 -81.26 -520.99
Price To Operating Cash Flows Ratio TTM -3.42 26.21 13.06 -3746.24 -93.1 -617.61
Price Cash Flow Ratio TTM -3.42 26.21 13.06 -3746.24 -93.1 -617.61
Income Statement (TTM)
ACHL VRTX REGN ALNY SGEN ARGX
Revenue $0B $11.02B $14.2B $2.25B $1.96B $2.19B
Gross Profit $-0B $9.49B $11.75B $1.92B $1.55B $1.96B
Gross Profit Ratio 0% 86.11% 82.74% 85.62% 79.1% 89.62%
EBITDA $-0.07B $0.49B $5.32B $-0.18B $-0.62B $0.11B
Net Income $-0.07B $-0.54B $4.41B $-0.28B $-0.61B $0.83B
EPS Diluted -1.74 -2.08 38.34 -2.16 -3.3 12.78
Balance Sheet (MRQ)
ACHL VRTX REGN ALNY SGEN ARGX
Long Term Debt $0B $1.66B $2.7B $1.25B $0.04B $0.03B
Total Liabilities $0.02B $6.12B $8.41B $4.17B $0.87B $0.7B
Total Equity $0.14B $16.41B $29.35B $0.07B $2.8B $5.5B
Total Investments $0B $6.65B $15.42B $1.73B $1.42B $1.93B
Total Debt $0B $1.75B $2.7B $1.3B $0.04B $0.04B
Total Assets $0.16B $22.53B $37.76B $4.24B $3.67B $6.2B
Cash Flow Statement (TTM)
ACHL VRTX REGN ALNY SGEN ARGX
Net Income $-0.07B $-0.54B $4.41B $-0.28B $-0.61B $0.83B
Inventory $0B $-0.52B $-0.62B $0.01B $-0.23B $-0.1B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.05B $-0.49B $4.42B $-0.01B $-0.45B $-0.08B
Capital Expenditure $-0B $-0.3B $-0.76B $-0.03B $-0.08B $-0.07B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 40.84
AARD Aardvark Therapeutics, Inc. Common Stock 9.17
ABCL AbCellera Biologics Inc. 4.39
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 7.035
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.4095
ABPWW 0.05
ABSI Absci Corporation 2.525
ABUS Arbutus Biopharma Corporation 3.65
ABVC ABVC BioPharma, Inc. 3.05
ABVX Abivax SA American Depositary Shares 80.87
ACAD ACADIA Pharmaceuticals Inc. 26.3
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.7452
ACGN Aceragen, Inc. 0.3849
ACHV Achieve Life Sciences, Inc. 3.02
ACIU AC Immune SA 2.085
ACLX Arcellx, Inc. 70.39
ETFs With Exposure to ACHL
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0.01 138.34
BIB ProShares Ultra Nasdaq Biotechnology 0 55.555
IBBQ Invesco Nasdaq Biotechnology ETF 0 23.46
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0.01 6.83875
Unlock